GENEART Awarded two US Patents for Successfully Tested HIV Vaccines
News Feb 21, 2008
The GENEART AG announces the award of the patents US 7,332,588 and US 7,323,557 titled "Genome of the HIV-1 inter-subtype (C/B') and use thereof" by the United States Patent and Trademark Office. The above-mentioned patents protect the use of specific custom-designed HIV gene sequences for the development as therapeutics or vaccines.
Recently, the now patent-protected gene sequences have been tested as HIV vaccine candidates on 40 test persons by the EuroVacc Foundation in a phase I clinical trial. The trial has turned out to be successful. The results of this study have been published in "The Journal of Experimental Medicine" (Vol. 205, 63-77).
In the trial, the prophylactic vaccination proved to be safe and well tolerated, and it triggered a strong and lasting immune response in 90 % of the vaccinated test persons in London and Lausanne. As the licensor, GENEART provided the patented gene sequences (structural design) for the tested vaccines.
The synthetic genes were custom-designed by the scientists at GENEART and the University of Regensburg. These genes serve as the basis for the vaccine candidates, which are used in the so-called "prime boost" procedure as naked DNA (DNA-HIV-C), and with a genetically modified small pox vaccine (NYVAC-HIV-C) as a carrier system.
The further clinical I/II studies with 120 test persons in Lausanne, London, Paris and Regensburg started already in the beginning of 2008, under the patronage of the European research cluster EuroVacc.
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE